Home > Divisions Codes & Standards > Bureaus, Offices & Programs Bureau of Code Services > Bureau of Code Services Bureau of Construction Project Review Office of Local Code Enforcement Office of Regulatory Affairs Bureau of Homeowner Protection Bureau of Housing Inspection Bureau of Rooming and Boarding House Standards Office of the Director The Elevator Safety unit registers all elevator devices in the State of New Jersey. Elevator devices consist of elevators (hydraulic, traction, winding drum, roped hydraulic, rack & pinion and limited use limited access), escalators, moving walks, dumbwaiters, wheel chair lifts, chair lifts and man lifts. The elevator subcode is regulated under the Uniform Construction Code in Subchapter 12. There are three choices a NJ municipality may make regarding the jurisdiction of the elevator subcode in its town. It may give jurisdiction to the State, it may hire its own local Subcode Official, or it may subcontract to a third party agency.
If the State has jurisdiction in a town, the Elevator Safety unit coordinates inspections between the owner, elevator company and the State. The unit conducts all cyclical and acceptance (inspections under permit) inspections. Owners are billed for inspections directly by the State. In all three circumstances, Municipal Construction Officials are expected to periodically review the list of registered elevator devices in their municipalities and bring any necessary changes to the Elevator Safety unit's attention via e-mail to elevatorsafetyunit@dca.nj.gov Click here to view the list of registered elevator devices. If the State has jurisdiction in a town, this unit also coordinates the Elevator Subcode portion of Plan Review and Permitting with the municipality and the applicant/owner. The unit reviews building plans containing elevator devices (for a partial release) at the municipality's office. All elevator (layouts) plans are reviewed (for a final release) at the State office, owners/applicants are billed and releases are completed.
The local Construction Official is notified of the elevator release and permit documentation is coordinated between the required parties. Technical assistance is given to all parties requesting help specific to the Elevator Subcode. Monitoring of Subcode Officials and Inspectors in municipalities and third party agencies is carried out routinely. A penalty enforcement process is utilized where violations are not abated timely. FORMSApplication for:* Elevator Registration* Seasonal Facility* Transfer of OwnerLifts pre-approval letter form, 06-19-2014Request for Final Acceptance Inspection For New WorkUCC-F150, Elevator Subcode Technical SectionUCC-F155, Elevator Subcode Technical Section - Multiple DevicesUCC-F160, Application for VariationUCC-F326, Elevator Devices - Accident/Incident Report PUBLICATIONSBulletin 94-7, Plans for Elevator Devices Construction Code Communicator article, Fall 1997 Elevator Safety Subcode Optional Elevator Inspection ProgramBridge the gap to mobility & independence with a stair lift from Centerspan
From Montauk to Brooklyn; Manhattan to Northern New Jersey; and all over the five boroughs, Centerspan is bringing stairway access and personal mobility to New York residents with our complete line of stairlift products! We offer the best stairlifts in the industry from trusted names such as Acorn, Harmar, Handicare, and Brooks. Our one year warranty on all stair lift installs will give you peace of mind as you enjoy the upper floors of your home again without worry! Imagine the safety and security of a new stairlift from Centerspan! Whether it's you or a loved one having difficulty with the stairs in your home, your new stair chair will safely deliver you to the top and bottom of your stairs with ease and comfort. Whether the stairway in your home is straight, curved, or outdoors, we have a stairlift that will suit your needs. Our straight rail stairlifts and curved stairlift products from Acorn can usually be installed within a week! Our outdoor stairlift is rugged, reliable, and weather-resistant to ensure long-lasting dependability.
All of our stairlift products are built with professional craftsmanship, and are loaded with features to ensure your stair lift stands the test of time. Battery backups ensure that your stairlift will operate even during a power outage. Our stairlifts easily fold away when not needed to allow normal stairway access. Call Centerspan today at 1-844-SAFE-STAIR to schedule a FREE evaluation of your needs, and achieve independence and safety with a new stairlift!With dual hydraulic lift arms and a design that has withstood the test of time, the Century Series offers all of the benefits of a BraunAbility wheelchair lift in a streamlined, economical package. The simplified electrical system offers trouble-free operation, while the non-hydraulic spring-loaded roll stop keeps the wheelchair securely on the wheelchair lift platform throughout the lifting cycle. 800 or 1,000lb lifting capacity Floor to ground lift heights up to 54" Excellent reliability and durability BraunAbility offers six versions of the Century 2 Wheelchair Lift, including usable platforms of 33" x 51", 34" x 51", and 34"x54".
The models also vary, based on the placement of the pump, the lifting capacity (800 or 1,000 lbs) and the overall floor to ground lift height (up to 54"). Please review the application guide for further detail. Downloadable Century 2 Information: Find Your Nearest BraunAbility Commercial Dealer »Dr. Shetty’s presentation to the Myositis Education and Support Program focused on inflammatory myopathies and their initial evaluation, testing, diagnosis, and treatment protocols. Inflammatory myopathies are muscle diseases characterized by muscle weakness. The three major inflammatory myopathies are polymyositis, dermatomyositis, and inclusion body myositis. Each type has different findings: One of the major effects of the inflammatory myopathies is difficulty in swallowing, known as dysphagia. If this occurs, it is important to bring this to the attention of your physician. Muscle disease can also be associated with certain endocrinological problems, such as thyroid abnormalities.
Toxic myopathies refer to myopathies that are caused by medications such as steroids, chloroquine, colchicine, and statins. Each type of inflammatory myopathy (polymyositis, dermatomyositis, and inclusion body myositis) has specific findings upon examination, electromyographic testing, muscle enzyme level, and muscle biopsy. People who have muscle disease generally present with the following upon examination: Onset can be gradual and progressive; there may be varying degrees of muscle pain or cramps. When these complaints are present, a detailed neurological exam is indicated in order to find the source of the weakness and to determine which muscles are affected. Blood tests are also obtained to check muscle enzyme levels and to determine the presence of associated rheumatologic or connective tissue disorder markers that may be associated with myositis or muscle diseases. These tests, in conjunction with renal (kidney) and liver tests, are used to monitor inflammation and to rule out the possibility of medication toxicity.
The blood tests monitor levels of creatine kinase (CK, also known as creatine phosphokinase [CPK]). A rise in the CK level may be the first sign of a muscle disease flare and can occur prior to muscle weakness. It should be noted that CK levels are variable and are affected by race, gender, genetics, cholesterol-lowering drugs and activity level. All of these tests are conducted in order to determine the specific type of myopathy a person has. Although family history can often be relevant, the absence of muscle disease in a family does not mean that the patient does not have muscle disease. History about family members is often incomplete. Many muscle diseases occur spontaneously or are not fully understood genetically. Further testing can include the use of electromyography (EMG) and imaging, such as MRI and ultrasound. These tests work in the following ways: The goal of treatment is to decrease muscle inflammation and to prevent further muscle loss or injury. Medical treatment is individualized, and there are no defined guidelines in the approach to treatment.
However, randomized controlled clinical trials are evolving in order to better define this. It is important to note that all treatment options, responses, and effects are personalized and that each individual will respond differently to a given plan. The physician will be able to assess your response to treatment based on your own report of the status of your disease, change in rash, and examination of muscle strength. As Dr. Shetty emphasizes, “Most importantly, the treatment is based on a very close interchange between physician and patient who, together, assess the response to immunosuppressive therapy. This dialogue enables the doctor and patient to arrive at a treatment plan that is optimal for the patient.” Factors that are taken into consideration for treatment are: Medications that are commonly used in myositis include corticosteroids and other immunosuppressive agents such as Imuran (Azothioprine), Cellcept, Methotrexate, and Rituxan (still in trial stages).
Although corticosteroids are often have a wide range of side effects, their effectiveness makes them an initial treatment approach. The dosing is individualized to the patient and weighed against potential side effects. Caution is urged against the prolonged use of high doses of steroids. It should also be noted that steroids can cause a myopathy, which is often reversed when steroid dose is tapered. Indications for use of immunosuppressives other than steroids include: progression of clinical symptoms, poor response to steroids, evidence of organ involvement, relapse when steroids are tapered, and undesirable effects from steroids (osteoporosis, cataracts, diabetes, hypertension acne, weight gain, and mood changes). IVIG is administered intravenously and is derived from pools of serum from healthy individuals. IVIG provides antibodies and has an immunomodulatory effect, which can be used to treat dermatomyositis and polymyositis where other treatments have not proved effective.